TMCnet News
Our Newsletter Is On Fire!! MNDP " Mundus Group Inc. Projected Revenues of $75 Million in 2010" :: Sign Up Today!!(M2 PressWIRE Via Acquire Media NewsEdge) STOCK MARKETING INC PRESENTS : (PINKSHEETS: MNDP) Mundus Group, Inc., (OTCBB: KEME) KEMET Corp., (OTCBB: CCTR) China Crescent Enterprises, Inc., (OTCBB: ISCR) instaCare Corp., (OTCBB: NNVC) NanoViricides, Inc., (OTCBB: ECTE) Echo Therapeutics, Inc. www.StockMarketingInc.com To sign up for our free Profiles & Alerts :: visit http://www.StockMarketingInc.com email us!! [email protected] or call 1-866-583-8960 ------------------------------------------------------------------------------------------------------------------------------------------------------------ (PINKSHEETS: MNDP - Mundus Group, Inc.) LATEST NEWS!! Mundus Group Inc. Projected Revenues of $75 Million in 2010 NEW YORK, NY, Jan 12, 2010 -- Mundus Group, Inc.'s (PINKSHEETS: MNDP) 2010 revenues have been estimated at $75 million dollars by Grass Roots Research and Distribution Inc. Mundus Groups subsidiary AirStar International, a market leader in Vertical Take Off and Landing (VTOL) Unmanned Air Vehicles (UAV), has had contracts with the US Army, US Navy, Northrop Grumman, and Guided System Technology, with more proposals lined up in the near future. Applications of AirStar products show to be almost limitless. AirStar UAV's have been used in a wide range of applications from weather forecasting to film work on Hollywood blockbusters like "Terminator Salvation." ------------------------------------------------------------------------------------------------------------------------------------------------------------ (OTCBB: KEME - KEMET Corp.) LATEST NEWS!! KEMET Announces Date for the December 2009 Quarterly Earnings Release GREENVILLE, S.C., Jan 12, 2010 -- KEMET Corporation (OTC Bulletin Board: KEME.OB), a leading manufacturer of tantalum, multilayer ceramic, solid aluminum, plastic film, paper and electrolytic capacitors will host a conference call at 9:00 AM (ET) on Thursday, January 28, 2010, to discuss its financial results for the third quarter ended December 31, 2009. To access the call via telephone, participants in the United States should dial 1-800-416-8033, and participants outside the United States should dial 1-706-643-0979. Participants should reference "KEMET Corporation" and Conference ID # 49881402. Participants can view a corresponding presentation from the KEMET website at www.kemet.com by clicking on the third quarter conference call link in the Investor Relations section of the website. The presentation will be available immediately prior to the beginning of the call. Following management's comments, there will be an opportunity for questions. In conjunction with the conference call, there will be a simultaneous live broadcast over the internet, which can be accessed at http://www.kemet.com/ir. A replay of the conference call will be available until midnight, February 11, 2010, through the same link. Also available in the Investor Relations section of the website is additional company information and a link to subscribe to KEMET news and financial releases. About KEMET KEMET Corporation (KEME.OB) applies world-class service and quality to deliver industry-leading, high-performance capacitance solutions to its customers around the world. KEMET offers the world's most complete line of surface-mount and through-hole capacitor technologies across tantalum, ceramic, film, aluminum, electrolytic, and paper dielectrics. Additional information about KEMET can be found at http://www.kemet.com. ------------------------------------------------------------------------------------------------------------------------------------------------------------ (OTCBB: CCTR - China Crescent Enterprises, Inc.) LATEST NEWS!! China Crescent Enterprises, Inc. Reviews $36 Million Contract Contribution to $100 Million 2010 Revenue Objective in Exclusive Webcast Conducted by CEO Paul Danner DALLAS, TX, Jan 12, 2010 -- China Crescent Enterprises, Inc. (OTCBB: CCTR) today released an on-demand Webcast reviewing the Company's recently announced three-year contract valued at $36 million to provide information and telecommunication technology services to Aoyuan Electronic Co. Ltd located in Dalian, China. The contract could contribute upwards of $10 million to China Crescent's revenue in 2010. Additionally, the Webcast discusses the potential benefit of the Company's outsourcing services offering toward the Company's $100 million 2010 revenue goal, the potential for further growth in the Chinese domestic market and beyond and the upcoming Virtual Town Hall. China Crescent reported over $40 million in annual revenue in both 2007 and 2008, and recently reported $30 million in revenue through the first nine months of the year ending September 30, 2009, with record net income of $1.8 million. China Crescent is a systems integration service provider in China that markets technology outsourcing services that include the sale and service of brand name technologies such as Microsoft, Oracle, Cisco, IBM, HP and Dell. A link to the Webcast titled 'China Crescent $36 Million Dalian Contract' is now available under Recent Webcasts on the corporate website at www.chinacrescent.com. China Crescent Virtual Town Hall January 22, 2010 China Crescent plans to release a 2009 Virtual Town Hall on January 22, 2010. The Virtual Town Hall agenda includes a review of 2009, a preview of the Company's plans for the year ahead and an outline of plans to evolve the Company's growth strategy while adopting lessons learned. The Virtual Town Hall is scheduled to be made available online to interested viewers on their own schedule and from their own location. Sign Up to Receive Regular China Crescent Investor Updates China Crescent sends regular email updates to its opt-in, permission-based email database. Interested investors can easily, safely and quickly register to receive these communications directly on the corporate website homepage (www.chinacrescent.com). Recipients can manage their own email contact profile and safely unsubscribe at any time. About China Crescent Enterprises, Inc. (www.chinacrescent.com) China Crescent Enterprises, Inc. reported over $40 million in profitable revenue in 2008. The Company is a technology leader in the rapidly developing Chinese market specializing today in software engineering, high quality software development and digital multimedia outsourcing services delivered to customers globally. At the same time, the firm is a systems integrator and value added reseller of major global hardware brands in the Chinese domestic market. Headquartered in Dallas with operations in Shanghai and Beijing, China Crescent bridges the gap between Western and Eastern business cultures to assist Western clients in realizing the advantages of the high quality, low cost technology products and services available from China. China Crescent also assists Western clients in localizing products and services to realize the tremendous growth potential available by expanding into the Chinese Market. ------------------------------------------------------------------------------------------------------------------------------------------------------------ (OTCBB: ISCR - instaCare Corp.) LATEST NEWS!! instaCare Corp. Finalizes MD@Hand Parallel Marketing Strategy LOS ANGELES, Jan 12, 2010 -- instaCare Corp. (OTC Bulletin Board: ISCR), a leading provider of prescription drugs, home testing products for the chronically ill, a leading fulfillment provider of direct to patient diabetes programs, and a leading developer of revolutionary cell phone centric e-health products and technologies, today announced that it has finalized its 2010 parallel marketing strategy for its cell phone-centric MD@Hand EMR/EHR appliance, which will include partnerships with traditional healthcare companies. The Company concurrently announced that it has engaged William N. Walling, Jr. CFA to review and report on the Company's guidance in an upcoming shareholder conference call. The Company has received six inquiries, expressions of interest, or outlines from a variety of traditional health care companies. Management is evaluating the Company's options through each of the potential partners, and the Board has asked management to contact three of the interested parties and engage in discussions with the goal of executing agreements later in 1Q 2010. Management also believes that additional interested parties will emerge during this process. Robert Jagunich Chairman of instaCare commented, "We have received inquiry from six entities including systems providers, insurers, a large commercial laboratory, and two health benefits management organizations. All of these companies have unique needs and have determined that to catch up to the quickly moving EMR and EHR standards and the coming national healthcare reform, the best available alternative would be to form a partnership to market our revolutionary technology or acquiring our technology outright." Interest in new methods to provide EMR/EHR products and services has accelerated as Congress has debated the health care reform bill, as health information technology vendors and insurance companies strive to improve their competitive position pending changes in the health care system. instaCare is poised at the sweet spot of these changes, able to provide its MD@Hand product and technologies that will allow any of the traditional health care companies to exploit an enviable position. Keith Berman Secretary and CFO of instaCare added, "We remain totally committed to monetizing our game-changing MD@Hand technology and we are pursuing partnerships with companies with a stated need that also provide services or products to or manage large doctor networks. The market reaction, including inquiries and proposals from software companies and insurers, has reinforced our confidence that we have not only the ideal product for the new healthcare marketplace, but perhaps our cell phone-centric solution is the only completed and ready-to-deploy product that will work in an environment where mandates are the order of the day." Mr. Jagunich concluded, "Our Board and an experienced and now growing team is evaluating these opportunities. Our goal is to move deliberately until the health care bills now in Congress become one law. When that happens, likely sometime in February, our plans will have been completed, our partners chosen and our patents filed. Finally, investors, speculators, funds and individuals have approached us -- some several times - seeking to collateralize our software and technology, loan us money we do not need, at terms we cannot accept, or provide us with repetitive capital raising schemes that are not in the best interests of our shareholders. We have politely declined all such requests and will continue to do so." The company also announced that its medical products distribution business continues to grow with expanded profit margins likely in 2010 as the business grows to scale. The pending healthcare legislation is likely to drive significantly increased demand for medical products, particularly diabetic testing products, as upwards of 30 million new patients become eligible for government subsidy or government insurance. The company strongly believes that is well-positioned to benefit from this surge which could double the company's diabetes testing business prior to any organic growth. About MD@Hand instaCare's MD@Hand technologies allow physicians to gain access to and securely store electronic medical records without the need of a stand-alone computer, tablet PC or PDA. The company has determined that no other offering provides a physician a suite of robust, secure internet based EMR, patient medical history applications, and proposed treatment protocols in a hand held mobile appliance, capable of use by a physician after 15 minutes of training. The company estimates that the Verizon Windows phones will allow EMR permanent storage for up to 5,000 patients for up to 10 years, or more. The Apple iPhone, Palm Pre, the Droid, and the Blackberry phones are equally impressive although permanent storage is slightly less. ------------------------------------------------------------------------------------------------------------------------------------------------------------ (OTCBB: NNVC - NanoViricides, Inc.) LATEST NEWS!! NanoViricides Invited to Present at the Biotech Showcase Conference in San Francisco WEST HAVEN, Conn., Jan 11, 2010 -- NanoViricides, Inc. (OTCBB: NNVC) (the "Company"), reports that the Company has been invited to present on January 12th at the Biotech Showcase(TM), a conference designed to showcase promising companies and technologies for partnering and investment purposes. Dr. Anil Diwan, President of NanoViricides will outline the Company's technology and the current drug programs. "We have received significant interest from many parties," said Eugene Seymour, MD, the CEO of the Company, adding, "and we have already set up several meetings during this Conference with both pharmaceutical companies and investment bankers. However, there can be no assurance that we will reach an agreement with any of the parties or that if we do reach an agreement, it will be on terms favorable to the Company." The Company now has four commercially important drugs in its pipeline, targeting a total market size of approximately $40 Billion. These drugs target HIV, all Influenzas, viral diseases of the external Eye, and Herpes Simplex viral infections including cold sores and genital herpes (HSV). In addition, the Company has R&D programs in collaborations with reputed institutions against several Neglected Tropical Diseases and agents of interest for Biosecurity. These include hemorrhagic fever viruses such as Ebola/Marburg, Dengue, and Rabies, among others. Our current drug programs include a pan-influenza drug candidate, "FluCide(TM)". This drug was recently reported to be highly effective against H1N1 influenza in an extremely lethal challenge animal model. All animals treated with FluCide((TM)) were still surviving when all animals treated with oseltamivir (Tamiflu(R)) were dead in 8 days. FluCide treated animals continued to survive for a whole extra week beyond those receiving extended oseltamivir treatment (14 days). This long survival time in this extremely lethal challenge model would suggest indefinite survival in other standardized animal models, according to experts. No other anti-influenza drugs in development have been tested with such severe lethal challenge. FluCide is designed to be effective against all influenza A strains and mutants. We anticipate FluCide to be effective against highly pathogenic avian influenzas such as H7 and H9, the epidemic bird flu virus H5N1 (various clades), the current novel H1N1/2009 virus, seasonal influenza viruses, and their mutations. The Company has previously reported that its anti-HIV drug candidate was >25X (or >2,500%) more effective than the oral HAART treatment comprising three drugs, on a drug load basis. This study employed a standard SCID-Hu Thy/Liv mouse model. Human lymphocytes implanted in a mouse, and infected with HIV, are treated with antiviral drugs in this model. It is very important to note that no adverse events were observed in the nanoviricide treated mice, while the HAART-treated mice exhibited clinical signs of side effects. HAART or "highly active anti-retroviral therapy" is a three-drug combination therapy currently in use in human clinical practice, and is regarded as the most effective therapeutic regimen against HIV. If these preliminary results are confirmed in further animal studies and in human clinical trials, the Company believes that HIVCide(TM) could very well result in a "Functional Cure" for HIV/AIDS. The Company has reported significant progress in its topical nanoviricide eye drops program. This drug is designed to treat most viral infections of the external eye, including adenoviral epidemic kerato-conjunctivitis (EKC) and herpes keratitis. The Company also recently reported that it has successfully added a new anti-HSV drug program to its pipeline this year. The Company's topical anti-herpes drug candidate has already demonstrated greater than 10,000-fold (>99.99%, or >4 logs) reduction in virus quantity in cell culture models of HSV-1 infection. Animal model studies of topical and genital herpes are planned. "We are now well poised to further develop our drug candidates with the objective of filing an IND application as soon as possible," said Dr. Eugene Seymour, MD, MPH, CEO of the Company. About the Biotech Showcase(TM) (Innovation -- Opportunity -- Collaboration): The Biotech Showcase(TM) will feature corporate presentations by 100+ innovative life science companies to an audience of public and private investors, business development executives and professional advisors who are interested in investment opportunities and collaboration. Public and private investors are always invited to attend the showcase on a complimentary basis. The Biotech Showcase(TM) was co-founded by Demy-Colton Life Science Advisors and EBD Group, two organizations that have a long and successful history building programs that meet the needs of the life sciences industry. Visit our website for more information: www.biotechshowcase.com. About NanoViricides: NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide(R) class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. ------------------------------------------------------------------------------------------------------------------------------------------------------------ (OTCBB: ECTE - Echo Therapeutics, Inc.) LATEST NEWS!! Echo Therapeutics Announces Major Milestone: The Completion of Product Development Work of its Revolutionary, Patented Prelude(TM) SkinPrep System Company Plans Clinical Trial Testing and Commercialization in Near-Term FRANKLIN, Mass., Jan 11, 2010 -- Echo Therapeutics, Inc. (OTC Bulletin Board : ECTE), a company developing the needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery, announced today that the Company has completed the product development work for its Prelude SkinPrep System and now has the commercially ready product to be used in final clinical trials. Echo anticipates that no further changes will be made to the Prelude SkinPrep System and that the current device will be the one used for sale, subject to FDA market clearance of the product. The final Prelude device replaces the prototype device used in earlier clinical trials and will be tested in the near-term in a study using LMX4 lidocaine cream which should form the basis for a 510-k filing with Ferndale Pharma Group for the enhanced delivery of lidocaine. The Company believes that the addressable market for enhanced, fast acting topical lidocaine exceeds $1 billion. "The completion of the product development work on our Prelude SkinPrep System, our skin preparation platform technology used for both transdermal drug delivery and skin preparation prior to the application of the Symphony tCGM glucose biosensor represents one of the most important milestone events in the Company's history," stated Patrick T. Mooney, M.D., Chairman and CEO of Echo Therapeutics. "We are now prepared to complete our clinical validation and begin commercialization efforts in enhanced topical lidocaine delivery. This next generation skin preparation device incorporates substantial improvements beyond the prototype used in earlier studies. We anticipate testing Prelude with LMX4 anesthetic cream for enhanced local dermal anesthesia in the near-term and subsequently seeking 510-k market clearance from the FDA." The Company also anticipates that the completed Prelude will be tested in the near future with its recently completed one-piece, cost-effective, single-use Symphony tCGM glucose biosensor in patients with diabetes and critically ill patients who require aggressive glucose monitoring. Prelude incorporates Echo's patented skin permeation control feedback technology into a comfortable, wireless, hand-held device used to prepare a small area of the skin for the non-invasive, biosensor and monitoring components of its Symphony tCGM system or for transdermal drug delivery. About Echo Therapeutics Echo is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System for transdermal drug delivery of a wide range of novel topical reformulations of widely-used, FDA-approved products. ------------------------------------------------------------------------------------------------------------------------------------------------------------ About StockMarketingInc.com StockMarketingInc.com is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by StockMarketingInc.com. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed. ((Comments on this story may be sent to [email protected])) (c) 2010 M2 COMMUNICATIONS |